- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01302600
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular Atrophy (SMA) Patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is a multicenter, double-blind, randomized, adaptive, parallel groups, placebo controlled 3-stage study in patients with SMA type 2 or non ambulant type 3.
Stage 1 DMC 3-month safety assessment: An independent Data Monitoring Committee (DMC)will assess the safety of olesoxime every 3 months.
Stage 2 Efficacy/futility analyses at one year: A first interim efficacy analysis will be performed after all patients have been treated for one year (52 weeks) in order to assess the need to continue the study to reach the planned objective. In the event of positive and significant results in favor of olesoxime, the study will be considered as successful and all patients will be switched to olesoxime to allow the assessment of the sustainability of the treatment effect and safety. If the results are significantly in favor of placebo, the study will be discontinued for failure (futility).
Stage 3 Efficacy and safety analysis at two years: The expected study duration is of 2 years (104 weeks) to show efficacy. If the study is not discontinued for futility or medication regimen is changed due to success, the study will therefore continue until planned completion i.e. 104 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ghent, Belgium, 9000
- University Hospitals
-
Leuven, Belgium, 3000
- University Hospitals
-
-
-
-
-
Bron, France, 69677
- Hôpital Femme-Mère-Enfant
-
Garches, France, 92380
- Hôpital Raymond Poincaré
-
Lille, France, 59037
- CHRU Hôpital R. Salengro
-
Marseille, France, 13385
- Hôpital La Timone
-
Montpellier, France, 34295
- CHU de Montpellier, Hôpital Gui de Chauliac
-
Paris, France, 75012
- Groupe hospitalier Armand-Trousseau
-
-
-
-
-
Essen, Germany, 45122
- University of Essen
-
Freiburg, Germany, 79106
- Universitat Klinikum Freiburg
-
Munchen, Germany, 80336
- Friedrich-Baur-Institute
-
-
-
-
-
Genova, Italy, 16147
- Istituto Giannina Gaslini
-
Messina, Italy, 98 125
- AOU Policlinico
-
Milano, Italy, 20122
- Centro Dino Ferrari, Milano
-
Milano, Italy, 20162
- NEuroMuscular Omnicentre (NEMO)
-
Roma, Italy, 165
- Bambino Gesu' Research Children's Hospital
-
Roma, Italy, 168
- Policlinico Universitario "Agostino Gemelli",
-
-
-
-
-
Utrecht, Netherlands, 3508 GA
- University Medical Center
-
-
-
-
-
Warsaw, Poland, 02-097
- Medical University of Warsaw
-
-
-
-
-
Birmingham, United Kingdom, B92 0AN
- Birmingham Heartlands Hospital
-
London, United Kingdom, WC1N 1EH
- Dubowitz Neuromuscular Centre
-
Newcastle, United Kingdom, NE1 3BZ
- Institute of Human Genetics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Weakness and hypotonia consistent with a clinical diagnosis of spinal muscular atrophy (SMA) type II or III
- Laboratory documentation of homozygous absence of SMNI exon 7 and/or deletion and mutation on other allele
- MFM relative score (percentage of the maximum sum of both dimensions) >= 15% (D1 + D2 score)
- HFMS score at baseline >= 3
- Non ambulant patients defined as patients with HFMS score =< 38
- Must be 3 years of age or older, but younger than 26 years of age, at time of enrolment
- Age of onset of symptoms =< 3 years of age
- Signed informed consent of patient and/or parents/guardian
- Laboratory results drawn within 31 days prior to start of study entry demonstrating no clinically significant abnormalities
- Ability to take the study treatment (tested at screening after informed consent)
Exclusion Criteria:
- Evidence of renal dysfunction, blood dysplasia, hepatic insufficiency, symptomatic pancreatitis, congenital heart defect, known history of metabolic acidosis, hypertension,significant central nervous system impairment, or neurodegenerative or neuromuscular disease other than SMA
- Any clinically significant ECG abnormality
- Any acute co-morbid condition interfering with the well-being of the subject within 7 days of enrolment including bacterial infection, viral infectious processes, food poisoning, temperature > 37.0 °C, the need for acute treatment or observation due to any other reason, as judged by the investigator; patient can be included after resolution of the acute event
- Use of medications intended for the treatment of SMA including riluzole, valproic acid, hydroxyurea, sodium phenylbutyrate, butyrate derivatives, creatine, carnitine, growth hormone, anabolic steroids, probenecid, oral or parenteral use of corticosteroids at entry, agents anticipated to increase or decrease muscle strength or agents with known or presumed histone deacetylase (HDAC) inhibition, within 30 days prior to study entry. Subjects who use a nebulizer or require an inhaler to steroids will be allowed in the study; however oral use of steroids is prohibited. The oral use of salbutamol is permitted with the following restrictions: patients should have been on salbutamol for at least 6 months before inclusion in the trial, with good tolerance. The dose of salbutamol should remain constant for the duration of the trial. The use of inhaled beta-agonists (for the treatment of asthma crisis for example) is allowed.
- Spinal rod or fixation for scoliosis within the past 6 months or anticipated need of rod or fixation within 6 months of enrolment.
- Inability to meet study visit requirements or cooperate reliably with functional testing
- Coexisting medical conditions that contraindicate travel, testing or study medications
- Olesoxime is contraindicated in subjects/patients who develop drug hypersensitivity to it or one of the formulation excipients including hypersensitivity to sesame oil.
- Patients with hemostasis disorders
- Patients with known biliary tract obstruction
- Current or planned pregnancy or nursing period
For Women: Failure to use one of the following safe methods of contraception:
- Female condoms, diaphragm or coil, each used in combination with spermicides
- Intra-uterine device
- Hormonal contraception in combination with a mechanical method of contraception
- Participation in any other investigational drug or therapy study within the previous 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Olesoxime
100 patients in this arm.
liquid suspension
|
Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
|
Placebo Comparator: Placebo
50 patients enrolled in this arm.
liquid suspension
|
0.1ml/kg once a day with food at dinner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor Function Measure
Time Frame: every 6 months
|
Motor function Measure (MFM) D1+D2 score
|
every 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety
Time Frame: every 3 months
|
every 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Enrico Bertini, MD, Bambino Gesu Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Spinal Cord Diseases
- Heredodegenerative Disorders, Nervous System
- Motor Neuron Disease
- Muscular Atrophy
- Atrophy
- Muscular Atrophy, Spinal
- Spinal Muscular Atrophies of Childhood
Other Study ID Numbers
- WN29836
- TRO19622 CL E Q 1275-1 (Other Identifier: Trophos ID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Muscular Atrophy Type II
-
Novartis Gene TherapiesActive, not recruitingSMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type I | Spinal Muscular Atrophy Type IIIUnited States, Belgium, France, Japan, United Kingdom, Italy, Taiwan, Australia, Canada
-
Marco CapogrossoRoche-GenentechNot yet recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy 4United States
-
Washington University School of MedicineActive, not recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type IIUnited States, Canada
-
University Hospital, Basel, SwitzerlandEnrolling by invitationSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type IIISwitzerland
-
WestatNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type IIIUnited States
-
Nationwide Children's HospitalNovartisActive, not recruitingSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type IUnited States
-
Scholar Rock, Inc.Active, not recruitingNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Anti-myostatin | Spinal Muscular Atrophy Type IIUnited States, Spain, Belgium, Germany, Netherlands, Poland, Italy, France, United Kingdom
-
Institut de Myologie, FranceRoche Pharma AGNot yet recruitingMuscular Atrophy, Spinal, Type II | Muscular Atrophy, Spinal, Type IIIFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Institut de Myologie, FranceCompletedSpinal Muscular Atrophy
Clinical Trials on Olesoxime
-
Hoffmann-La RocheTrophos SACompleted
-
Hoffmann-La RocheCompletedMuscular Atrophy, SpinalBelgium, United Kingdom, Germany, France, Italy, Netherlands, Poland
-
Hoffmann-La RocheHôpital de la Timone; SGS S.A.; STRAGEN ServicesCompletedRelapsing Remitting Multiple SclerosisFrance
-
Hoffmann-La RocheCompletedChemotherapy-Induced Peripheral NeuropathyFrance
-
Hoffmann-La RocheEuropean CommissionCompletedAmyotrophic Lateral SclerosisBelgium, France, Germany, Spain, United Kingdom